| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4585 | Sarafloxacin | Broad spectrum antibiotic |
|
| DCC4586 | Sarcolipin | Regulator of the sarco-endoplasmic reticulum Ca -ATPase (SERCA1a), significantly slowing down the E2 to Ca2.E1 transition of SERCA1a while it affects neither phosphorylation nor dephosphorylation |
|
| DCC4587 | Sarcolipin Palmitoylated | Regulator of the sarco-endoplasmic reticulum Ca -ATPase (SERCA1a), significantly slowing down the E2 to Ca2.E1 transition of SERCA1a while it affects neither phosphorylation nor dephosphorylation |
|
| DCC4588 | Sard033 | Novel Highly Potent Selective Androgen Receptor Degrader (SARD) |
|
| DCC4589 | Sard279 | Novel Potent Selective Androgen Receptor Degrader (SARD) |
|
| DCC4590 | Sarmustine | Covalent Antineoplastic Agent |
|
| DCC4591 | Sars-cov 3clpro-in-7d | Novel potent SARS-CoV-2 3CLpro inhibitor with IC 50 value of 73 nM |
|
| DCC4592 | Sars-cov-2 Mpro Inhibitor E24 | Novel SARS-CoV-2 Main Protease (Mpro) Inhibitor, inhibiting viral replication with a nanomolar EC 50 value (844 nM) in SARS-CoV-2-infected Vero E6 cells, impairing SARS-CoV-2 replication in human lung epithelial cells and human-induced pluripotent stem ce |
|
| DCC4593 | Sars-cov-2 Nsp14 Mtase Inhibitor 16 | Novel SARS-CoV-2 nsp14 Methyltransferase inhibitor |
|
| DCC4594 | Sars-cov-2 Nsp14/16 Inhibitor 2a | Novel potent SARS-CoV-2 MTase Nsp14 and Nsp16 inhibitor |
|
| DCC4595 | Satavaptan | Selective non-peptide vasopressin V2 receptor antagonist |
|
| DCC4596 | Satavaptan Fumarate | Selective non-peptide vasopressin V2 receptor antagonist |
|
| DCC4597 | Sat-in-3 | Novel inhibitor of salmonella serine acetyltransferase (SAT), the enzyme that catalyzes the rate-limiting step of L-cysteine biosynthesis |
|
| DCC4598 | Saussureamine C | Inhibitor of H274Y and N294S mutants |
|
| DCC4599 | Sazetidine-a Dihydrochloride | Subtype-selective α4β2 nicotinic acetylcholine receptor partial agonist |
|
| DCC4600 | Sb1404 | PPARγ covalent ligand |
|
| DCC4601 | Sb1495 | Novel reversible covalent inhibitor of the cyclin-dependent kinase 5 (Cdk5)-mediated phosphorylation of PPARγ at Ser245, a key factor in the insulin-sensitizing effect of PPARγ-targeted drugs |
|
| DCC4602 | Sb1617 | Novel neuroprotective agent, suppressing abnormal tau protein aggregation |
|
| DCC4603 | Sb-203347 | Selective, active-site-directed 14 kDa PLA2 inhibitor, totally inhibiting LT and PAF formation, while prostanoid formation was not altered |
|
| DCC4604 | Sb-209670 | Dual ETA and ETB receptor antagonist |
|
| DCC4605 | Sb-220025 Trihydrochloride | Potent, specific inhibitor of human p38 mitogen-activated protein (MAP) kinase |
|
| DCC4606 | Sb-226552 | Potent and selective agonist for the human ß3-adrenoceptor |
|
| DCC4607 | Sb-239272 | Inhibitor of p38 MAPK |
|
| DCC4608 | Sb-243213 Dihydrochloride | Selective 5-HT2C_receptor>5-HT2C inverse agonist |
|
| DCC4609 | sb-258719 Hydrochloride | Selective 5-HT7 receptor antagonist |
|
| DCC4610 | Sb2602 | Novel selective mTOR inhibitor |
|
| DCC4611 | Sb-267268 | Nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reducing angiogenesis and VEGF expression |
|
| DCC4612 | Sb-277011a Dihydrochloride | Selective dopamine D3 receptor antagonist |
|
| DCC4613 | Sb-284851-bt | Selective p38a kinase inhibitor, inhibiting Brd4 |
|
| DCC4614 | Sb-354364 | AntiMycobacterium tuberculosis agent |
|
